Strategic Wealth Partners Ltd. Has $2.69 Million Holdings in Becton, Dickinson and Company (NYSE:BDX)

Strategic Wealth Partners Ltd. lowered its stake in shares of Becton, Dickinson and Company (NYSE:BDXGet Rating) by 6.1% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 10,127 shares of the medical instruments supplier’s stock after selling 660 shares during the period. Strategic Wealth Partners Ltd.’s holdings in Becton, Dickinson and were worth $2,694,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in BDX. Orion Portfolio Solutions LLC boosted its position in shares of Becton, Dickinson and by 10.7% during the first quarter. Orion Portfolio Solutions LLC now owns 1,181 shares of the medical instruments supplier’s stock valued at $314,000 after buying an additional 114 shares during the last quarter. BNP Paribas Arbitrage SA grew its stake in shares of Becton, Dickinson and by 368.2% in the 1st quarter. BNP Paribas Arbitrage SA now owns 252,323 shares of the medical instruments supplier’s stock worth $67,118,000 after acquiring an additional 198,435 shares in the last quarter. O Brien Greene & Co. Inc raised its holdings in shares of Becton, Dickinson and by 1.4% in the first quarter. O Brien Greene & Co. Inc now owns 23,195 shares of the medical instruments supplier’s stock valued at $6,170,000 after purchasing an additional 310 shares during the last quarter. Wealthfront Advisers LLC raised its holdings in shares of Becton, Dickinson and by 26.7% in the first quarter. Wealthfront Advisers LLC now owns 26,769 shares of the medical instruments supplier’s stock valued at $7,121,000 after purchasing an additional 5,637 shares during the last quarter. Finally, Continuum Advisory LLC purchased a new stake in shares of Becton, Dickinson and in the first quarter valued at about $706,000. 86.74% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CEO Thomas E. Polen, Jr. sold 9,500 shares of the business’s stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $265.13, for a total transaction of $2,518,735.00. Following the completion of the transaction, the chief executive officer now directly owns 28,878 shares in the company, valued at $7,656,424.14. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other Becton, Dickinson and news, CEO Thomas E. Polen, Jr. sold 9,500 shares of the business’s stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $265.13, for a total value of $2,518,735.00. Following the completion of the transaction, the chief executive officer now owns 28,878 shares of the company’s stock, valued at approximately $7,656,424.14. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Samrat S. Khichi sold 9,185 shares of the business’s stock in a transaction that occurred on Tuesday, August 9th. The stock was sold at an average price of $260.44, for a total transaction of $2,392,141.40. Following the completion of the transaction, the executive vice president now directly owns 5,928 shares of the company’s stock, valued at approximately $1,543,888.32. The disclosure for this sale can be found here. Insiders sold a total of 19,160 shares of company stock worth $5,036,751 over the last ninety days. 0.50% of the stock is owned by corporate insiders.

Becton, Dickinson and Price Performance

Shares of NYSE BDX opened at $256.78 on Wednesday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.90 and a current ratio of 1.35. The stock has a market cap of $73.23 billion, a PE ratio of 44.27, a price-to-earnings-growth ratio of 3.44 and a beta of 0.57. Becton, Dickinson and Company has a fifty-two week low of $231.46 and a fifty-two week high of $280.62. The stock has a fifty day moving average of $251.33 and a 200-day moving average of $255.00.

Becton, Dickinson and (NYSE:BDXGet Rating) last issued its quarterly earnings data on Thursday, August 4th. The medical instruments supplier reported $2.66 EPS for the quarter, beating the consensus estimate of $2.50 by $0.16. The company had revenue of $4.64 billion during the quarter, compared to analysts’ expectations of $4.47 billion. Becton, Dickinson and had a net margin of 8.88% and a return on equity of 14.55%. Becton, Dickinson and’s revenue for the quarter was down 5.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.74 earnings per share. Equities research analysts anticipate that Becton, Dickinson and Company will post 11.31 earnings per share for the current year.

Becton, Dickinson and Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, September 30th. Stockholders of record on Friday, September 9th will be given a dividend of $0.87 per share. The ex-dividend date of this dividend is Thursday, September 8th. This represents a $3.48 dividend on an annualized basis and a dividend yield of 1.36%. Becton, Dickinson and’s dividend payout ratio (DPR) is currently 60.00%.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on BDX. Stifel Nicolaus decreased their price target on Becton, Dickinson and from $290.00 to $280.00 in a research report on Monday, July 18th. StockNews.com upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a report on Saturday. Morgan Stanley decreased their price objective on shares of Becton, Dickinson and from $282.00 to $272.00 and set an “overweight” rating for the company in a report on Friday, July 15th. Wells Fargo & Company upgraded shares of Becton, Dickinson and from an “equal weight” rating to an “overweight” rating and set a $275.00 price target for the company in a research note on Friday, June 24th. Finally, The Goldman Sachs Group raised their target price on Becton, Dickinson and from $278.00 to $319.00 and gave the stock a “buy” rating in a research report on Tuesday, August 16th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $277.63.

Becton, Dickinson and Company Profile

(Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

See Also

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.